Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0021051 (immunodeficiency)
 71,517 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Parvovirus B19 causes persistent erythroid aplasia in immunocompromised hosts. From April through July 1996, we encountered five adult patients presenting with reticulocytopenia and fever caused by parvovirus B19 infection. The reticulocyte count of four patients with normal immunity recovered within two weeks after the onset of fever. However, in the one remaining patient with common variable immunodeficiency (CVI), reticulocytopenia, and other symptoms including fever and the elevation of lactate dehydrogenase (LDH) levels persisted beyond 16 days of onset. Although the DNA of parvovirus B19 was detected in the peripheral blood of the CVI patient, neither immunoglobulin Ig-G nor Ig-M antibodies specific to the virus were detectable. We administered 50 mg/kg of Ig to the CVI patient for six days. The reticulocyte count recovered promptly on the sixth day of the treatment and parvovirus B19 DNA was not detectable 30 days after therapy. This indicates that although patients with CVI may be susceptible to persistent erythroid aplasia during an endemic of parvovirus B19, the complication can be treated successfully with relatively low-dose Ig.
 ...
PMID:Successful treatment of persistent erythroid aplasia caused by parvovirus B19 infection in a patient with common variable immunodeficiency with low-dose immunoglobulin. 1007 14

The hepatitis B and C viruses (HBV and HCV) and the human immunodeficiency virus (HIV) are the main causes of viral vasculitis in humans. The vascular lesions are classically ascribed to a variable combination of circulating immune complex deposition, cryoglobulinemia, and endothelial cell infection. Other viruses that can cause human vasculitis include the herpes viruses and parvovirus B19. The usual clinical manifestations of the viral infection are sometimes overshadowed by the vasculitis, which can be inaugural. With the exceptions of cytomegalovirus-and VZV-induced vasculitis, no specific treatments are available. A viral infection should be looked for routinely in patients with local or systemic vasculitis that does not admit of an obvious explanation.
 ...
PMID:[Viral vasculitis not related to HBV, HCV and HIV]. 1021 17

Necrotizing vasculitis is a heterogeneous group of systemic diseases characterized by inflammation of blood vessel walls. There is current agreement that viral infections can play a central role in the pathophysiology of systemic vasculitides responsible for a broad spectrum of clinical patterns. The hepatitis B and C viruses (HBV and HCV), the parvovirus B19, the human immunodeficiency virus, the HTLV 1, and the cytomegalovirus are the viruses most often implicated. Only the HBV and HCV are associated with fairly well-defined clinical pictures. The conventional management of systemic vasculitis rests on administration of a corticosteroid with an immunosuppressive (usually cyclophosphamide). The decision to treat rests on the nature and severity of the vasculitis. In viral vasculitis, the goal of therapy is to treat both the systemic condition and its cause at the same time. In this situation, conventional immunosuppressive therapy promotes perpetuation of the viral infection, exposing the patient to chronic lesions and to relapses. Antiviral therapy has demonstrated clear evidence of efficacy in vasculitis related to the HBV and, to a lesser degree, the HCV. For the other viruses data, in the literature are scant.
 ...
PMID:[Treatment of viral vasculitis]. 1021 19

Genetic diagnosis is a revolutionary method that makes possible simultaneous viral isolation (detection) and identification. The method is so specific, sensitive, and rapid (non-culture) that leads not only to the diagnosis of viral infection, but also to prediction of the chemotherapy, monitoring during the therapy, and judging the efficacy of the treatment. Moreover, it contributes to understanding the disease pathophysiology. The qualitative results are sufficient for diagnosis, but quantitative analysis is sometimes necessary for the prediction of the efficacy and monitoring during treatment. It occasionally requires the numbers of genomic expression, the number of DNA/RNA copies, and the detection of point mutations for drug resistance. Many emerging and re-emerging infectious diseases, such as AIDS and viral hepatitis, are induced by viral infection via blood. The main causative agents of blood-borne viral infection are hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), human T cell leukemia virus type 1 (HTLV1), cytomegalovirus (CMV), Epstein-Barr virus (EBV), and human parvovirus B19. They play main roles in viral hospital infection. The risk of them being transmitted by transfusion of screened blood is very low, but it is always possible that infection may occur in a window period even after extensive blood screening tests. Therefore, to shorten a window period, genetic examinations will be accepted for screening tests in the near future. Prioritization of genetic examinations is needed to select the adequate method and sampling. After examinations, false positive and false negative results have to be extensively read out whether due to contamination or inhibition by agent such as heparin and hemoglobin. The causative virus should be decided by carefully eliminating passenger viruses or latent viruses. Because genetic examinations are so useful but occasionally yield false positive and negative results, genetic diagnosis should be judged totally by combination with other examinations, clinical signs, and clinical symptoms.
 ...
PMID:[The role of genetic diagnosis in clinics--from the choice of ordering until reading the data]. 1059 Jun 77

Various methods are described for the elimination of infectious viruses from activated prothrombin complex concentrates (aPCCs) and for the analysis of the final products (AUTOPLEX T and FEIBA VH). Viruses of concern in human plasma-derived products are enveloped (hepatitis B and C, cytomegalovirus, Epstein-Barr virus, and human immunodeficiency virus [HIV]) and nonenveloped (hepatitis A and parvovirus B19). Donated blood used for AUTOPLEX T is screened for antihepatitis C, HBsAg, anti-HIV types 1 and 2, and p24 antigen. Plasma pools utilized for raw materials are also tested by PCR for HIV and hepatitis C virus. Partial virus inactivation and partitioning are achieved by purification of the aPCC. Further reduction of virus infectivity is accomplished by lyophilization and dry-heat treatment. Each step undergoes virus elimination validation studies in which a relevant sample is 'spiked' with the appropriate virus or model virus. The total reduction in virus from raw material to final product can then be calculated. For AUTOPLEX T the cumulative log10 reduction factors for several viruses vary from 4.2 to 14.3. This ensures an exceptionally high margin of safety. Definitive evidence for product safety was obtained by clinical observation of treated patients. The viral inactivation process of AUTOPLEX T involves a four-tier viral safety program, including Cohn alcohol fractionation and dry-heat treatment, in place of the two-stage vapour-heating process for FEIBA.
 ...
PMID:Efficacy of viral clearance methods used in the manufacture of activated prothrombin complex concentrates: focus on AUTOPLEX T. 1059 84

Anemia is generally attributed to zidovudine therapy in human immunodeficiency virus (HIV)-infected patients, although parvovirus B19 infection has been reported as a rare cause. We report on a 24-year-old homosexual man infected with HIV who presented with anemia. He had received aggressive daily antiretroviral therapy (zidovudine 600 mg, lamivudine 300 mg, and saquinavir 1,800 mg) for 2 years. At the time of admission, his CD4+ count was 10 x 10(6) cells/L. A bone marrow aspirate smear showed a marked decrease in erythropoiesis and immunocytochemical staining for parvovirus B19 was positive. Parvovirus B19 viral DNA was detected in the peripheral blood using a polymerase chain reaction-based assay. Serologic studies were positive for parvovirus B19 immunoglobulin (Ig)M antibodies, but negative for IgG antibodies. The patient was treated with packed red blood cell transfusion. Zidovudine was stopped and replaced with zalcitibine 2.25 mg daily after anemia occurred. He did not receive intravenous Ig therapy because of its cost. After discontinuation of zidovudine for 1 year, anemia persisted and the patient depended on regular blood transfusions to control the anemia. This case emphasizes that, in addition to drug-related causes, parvovirus B19 infection should be included in the differential diagnosis of chronic anemia in HIV-infected individuals.
 ...
PMID:Parvovirus B19 infection in a human immunodeficiency virus-infected patient with anemia. 1077 32

Since the advent of solvent detergent (S-D) treatment for inactivation of enveloped viruses, there has been no transmission of human immunodeficiency virus, hepatitis B virus, or hepatitis C virus by treated blood products. However, shortly after the introduction of S-D treatment, transmission of hepatitis A with S-D treated factor concentrates was reported in Germany, Italy, Ireland, the United States and South Africa, and this raised awareness of the potential for blood transmission of non-enveloped viruses in general. This report summarizes the physical and epidemiological features of three non-enveloped viruses, hepatitis A virus, parvovirus B19, and the recently identified TT virus, and their transmission by blood and blood products.
 ...
PMID:Non-enveloped viruses transmitted by blood and blood products. 1079 88

The blood borne viruses must be separated into major and minor agents. Major viruses transmissible by blood transfusion are human immunodeficiency virus (HIV) and hepatitis B and C viruses (respectively HBV, HCV). The prevalence of virological markers in French blood donors has been continuously decreasing since the implementation of serological screening methods as soon as they were available. In 1998, the prevalences (per 10,000 donations) were 0.17 for antibody to HIV, 0.08 for antibody to human T-cell leukemia virus (HTLV), 2.23 for hepatitis B surface antigen (HBs Ag) and 2.52 for antibody to HCV. The values are, of course, higher in new donors when compared to regular donors: approximately five-fold for HIV, 50-fold for HCV and 300-fold for HBs Ag. The remaining major questions concern the residual risk due to infectious donations which could escape the preventive measures. It seems evident that the major risk is imputable mainly to donations collected during the window period. During the 1996-1998 period, the residual risk for HIV was 1 out of 1,350,000 donations, 0 for HTLV, 1 out of 375,000 for HCV, and 1 out of 220,000 for HBV. A few cases of "immunosilent" patients have been reported. They remain exceptional. The first data collected after the implementation of nucleic acid technology (NAT) confirm the very low residual risk. The recent introduction of leukodepletion probably brought an important contribution to diminishing the risk of transmission of leucotropic viruses such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesviruses-6, -7 and -8, and HTLV. If the purification process of plasma-derived medicinal products including inactivation procedures makes it possible to be confident with the elimination of infectivity due to enveloped viruses, the detection of nucleic acid sequences derived from naked viruses in plasma pools such as parvovirus B19 or hepatitis A virus (HAV), and/or the introduction of a nanofiltration step during the purification process, when possible, may greatly contribute to their safety. The emergence of a new form of the Creutzfeldt-Jakob disease (nvCJD) introduces a new series of questions about the safety of blood products that, although the risks appear limited, are not yet resolved.
 ...
PMID:[Viruses and unconventional transmissible agents: update on transmission via blood ]. 1091 17

The evolution of viruses contributes to their diversification, whether it be a result of their own replication, or host-pressure dependent. Certain viral types, groups or subtypes are therefore found in certain regions of the world or in certain populations. The development of blood screening reagents is nearly always based on viral antigens or viral sequences derived from 'prototype' strains or antibodies raised against these prototype strains. Therefore in situations where an individual is infected by a viral strain that is genetically and antigenically distantly related to the prototype strain used in the development of the test, screening failure may occur. In the present article, this has been illustrated via 3 models, the human immunodeficiency virus (HIV), the hepatitis B virus (HBV), and the B19 parvovirus. Viral diversity also has a negative effect on the prevention of blood-transmitted viral infections. The example provided concerns vaccination failure and/or seroprophylaxis against hepatitis B.
 ...
PMID:[Genetic diversity of viruses. Consequences for screening and prevention]. 1110 32

Several reports have noted pancytopenia associated with Human parvovirus B19 (PVB19) or Ebstein-Barr virus (EBV) infections in patients who have no history of immunodeficiency. To our knowledge, we report the first case of severe aplastic anemia associated with both EBV and PVB19 infections in a previously healthy 22-year-old man. He was admitted to our hematology service due to anemia and thrombocytopenia. He had no symptoms or signs of infections of these viruses. His bone marrow biopsy revealed a hypocellular marrow. Specific IgM and IgG antibodies to EBV and PVB19 were elevated. EBV and PVB19 virus genomes were detected by PCR in the bone marrow nucleated cells and the peripheral blood lymphocytes. Two months after treatment with prednisone, acyclovir, and intravenous immune globulin (IVIg), the genomes of both these viruses disappeared. However, his transfusion requirement for platelet suspensions and packed red blood cells persisted. The patient underwent allogeneic bone marrow transplant (allo-BMT) and has had an enduring complete hematological response for 8 months.
 ...
PMID:Successful treatment of severe aplastic anemia associated with human parvovirus B19 and Epstein-Barr virus in a healthy subject with allo-BMT. 1144 38


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>